← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lifepharms, Inc.
New London, CT
$9,274,176
Total funding
11
Grants
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,274,176 · 11
By mechanism
U01$4,374,177 · 1
R43$2,477,465 · 8
R44$2,422,534 · 2
Investigators at Lifepharms, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Inhibitors of poxvirus enzymes as novel drugs$907,054
U01 · FY2005 · AI
Inhibitors of poxvirus enzymes as novel drugs$896,022
U01 · FY2009 · AI
Inhibitors of poxvirus enzymes as novel drugs$870,266
U01 · FY2008 · AI
Inhibitors of poxvirus enzymes as novel drugs$861,830
U01 · FY2007 · AI
Inhibitors of poxvirus enzymes as novel drugs$839,005
U01 · FY2006 · AI
Antifungal therapy against drug resistant fungal pathogens.$774,112
R44 · FY2015 · AI
Antifungal therapy against drug resistant fungal pathogens.$743,940
R44 · FY2016 · AI
Discovery of cell cycle inhibitors from natural products$464,946
R44 · FY2005 · CA
Discovery of cell cycle inhibitors from natural products$439,536
R44 · FY2006 · CA
Discovery of novel antibacterials from a mushroom natural product library$378,012
R43 · FY2009 · AI
Novel antifungals for Immunocompromised/HIV patients.$300,000
R43 · FY2011 · AI
The development of a novel antifungal for drug resistance$300,000
R43 · FY2025 · AI
Discovery of novel agents against M. tuberculosis.$300,000
R43 · FY2010 · AI
Novel Antibacterial Scaffold from Natural Products$300,000
R43 · FY2011 · AI
Hsp90 inhibitors to combat antifungal drug resistance.$299,998
R43 · FY2012 · AI
Novel Antibacterial Scaffold from Natural Products$287,757
R43 · FY2012 · AI
Nucleoside hydrolase Inhibitors from natural products for Leishmania$211,698
R43 · FY2010 · AI
POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES$100,000
R43 · FY2001 · CA